Washington, DC (openPR) 2 October 2010

Global Health Progress (GHP) has published a new leaflet highlighting Russiaâ? Commitment to the development and promotion of the biotechnology industry. Although the biopharmaceutical industry in Russia has been less developed than other markets, has the industry in the implementation of public policies, the pharmaceutical research and development (R & D) treatment for life changes, be made to contribute to ensuring high quality, well-paid jobs in to improve the region and increase the number of trials available to the public access to medicines and the global burden of disease.

Russia currently accounts for about 0.5% of the biotechnology market in the world, two thirds of biopharmaceuticals. In 2010, the value of the pharmaceutical market in Russia is estimated at about 0.2 billion euros, compared with 0.4 billion U.S. dollars in 2006. Analysts said the Russian market is expected to be accumulated at an annual growth rate of 8.3% over the next years and over 53% of the pharmaceutical market in Russia is growing innovative medicines.

As part of a national plan of 10 years to promote the biotechnology, the government shall take the measures to strengthen Russiaâ goal? S of pharmaceutical research and development (R & D) areas that are traditionally strong. For example, special economic zones will attract investors in the biotechnology and related innovations to market. In addition, the Russian government is investing in? Biopolis, â? Cluster of R & D in biotechnology and related industries.

Russia is known for its academic staff is highly trained and know the biopharmaceutical industry has emerged as an important source of high quality, highly skilled jobs. Since the presence of elevated biopharmaceutical companies, not so the pool of highly qualified doctors, scientists and researchers. According to Burrill & Company, the biopharmaceutical industry currently employs around 12,000 people with the average salary for a Ph.D. Scientists in Russia about 800

Russia currently ranks 12 out of 25 in terms of active clinical trials relative 1,084 locations with an average annual growth rate of 33%. But in February 2010 there were 304 drugs in development in Russia, one of the fastest annual growth. The growth of the global clinical trials and provide health benefits, including the dissemination of medical knowledge and effective medical practice, patients better access to quality care and improve access to medicines. Clinical trials can also contribute to the global disease burden on the Russian population.

Russiaâ? s recognition that the biopharmaceutical industry to develop the potential of tomorrow? s populationa improve medication? s access to medicines, creating economic growth and alleviate populationa? ? s disease burden provided for a strong investment and progress in the region. Russian Prime Minister Vladimir Putin has the obligation to a stressed? We have significant resources for the development of promising fields such as nanotechnology and biotechnology assigned, nuclear energy, aerospace and other research.â ????

Please see full PDF

more information and a list of sources. For more information about this medicine, public-private partnerships that will help investment in research and development and improving access to medicines in the biopharmaceutical market? S global expansion, please visit the Global Health Progress.

progress in global health policy:

Global Health Progress also supports efforts to raise awareness and mobilize resources for health challenges in developing countries by private local leaders and international experts, policy makers, donor governments and industry address.

On the Web: www.globalhealthprogress.org
http://twitter.com/globalhealth

http://facebook.com/group.php?gid=35156473766

http://linkedin.com/groups?home=&gid=2972068

>


clear = “all”
Nurse salary